The research further supports zuranolone as a potential episodic treatment for people with MDD, according to the study authors.
Eleven new analyses on zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder (MDD) and postpartum depression, indicate the potential of the medication to improve the symptoms of depression. These data were presented at the 2022 Psych Congress in New Orleans,.
Zuranolone is a neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). The medication acts as a major part of the inhibiting signaling pathway of the brain and central nervous system, and contributes to regulating brain function.
The ongoing open-label, longitudinal SHORELINE study in patients with MDD (30 mg cohort, 50 mg cohort) found the median time to the first repeat treatment course for patients who responded to the initial 14-day treatment course was 135 days for the completed 30 mg cohort and 249 days for the ongoing 50 mg cohort. The research further supports zuranolone as a potential episodic treatment for people with MDD, according to the study authors.
Some of the key findings from the completed 30 mg cohort of the SHORELINE study, other clinical data and health economics and outcomes research (HEOR), and patient survey, include:
“The data presented at Psych Congress highlight the rapid and sustained improvement in depressive symptoms seen with zuranolone in clinical trials and reinforce its potential to be an as-needed treatment in MDD,” said Greg Mattingly, MD, associate clinical professor, Washington University, in a press release. “Depression is a leading contributor of disability worldwide and importantly awareness has grown during the past few years of the global pandemic. We can and must do more to help people living with MDD and those that care about them overcome the challenges of this disease.”
Biogen and Sage Therapeutics Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone. Biogen. September 19, 2022. Accessed September 22, 2022. http://media.biogen.com/news-releases/news-release-details/biogen-and-sage-therapeutics-present-new-analyses-psych-congress